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Introduction
Gestational trophoblastic disease (GTD) encompasses
hydatidiform mole and gestational trophoblastic tumor
(GTT) including invasive mole, choriocarcinoma, and
placental site trophoblastic tumor. The frequency of
hydatidiform mole is approximately one per 1,000
pregnancies in Western countries. In Asian countries,
the rate is up to 15 times higher than in the USA [1].
Most patients with GTD can be successfully cured
using chemotherapy. It is strongly recommended that
pregnancy be delayed for 1 year or more after chemo-
therapy, due to the genetic damage and teratogenic
effects of anti-cancer agents [2], and 1 year or more
after the completion of human chorionic gonadotropin
(hCG) monitoring.
In this study, we followed the outcome in 22 patients
with GTD treated in the past 5 years in the gynecologic
department of Chung Shan Medical University Hospital.
Follow-up was for 1 year or more using standard hCG
monitoring.
SUMMARY
Objective: To determine outcome in patients with hydatidiform mole and gestational trophoblastic tumor after
successful treatment.
Materials and Methods: This was a retrospective review of outcome in 22 patients with gestational trophoblastic
disease (GTD) who completed human chorionic gonadotropin (hCG) follow-up for 1 year or more after treatment
between 1999 and 2003.
Results: The mean age of patients with GTD was 32.5 years. Sixteen patients (72.7%) with hydatidiform mole
and six (27.3%) with gestational trophoblastic tumor were evaluated. One patient (4.5%) with metastatic
choriocarcinoma experienced complete remission after debulking surgery followed by chemotherapy. Fifteen
patients (68.2%) with persistent GTD were diagnosed by hCG follow-up. After at least 1 year, eight patients
(36.4%) conceived and six (27.3%) delivered a healthy term baby. All patients experienced an excellent prognostic
outcome following chemotherapy and there were no deaths.
Conclusion: GTD exhibited an excellent response to chemotherapy and subsequent successful pregnancy was
achieved in some patients 1 year or more after completion of treatment. Patients without previous childbirth
desired subsequent pregnancy. Patients must be followed-up carefully after treatment and during conception.
[Taiwanese J Obstet Gynecol 2005;44(2):139–142]
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Materials and Methods
From 1999 to 2003, 22 patients with hydatidiform
mole and GTT were identified by reviewing medical
charts in the gynecologic department of Chung Shan
Medical University Hospital. Among these, 16 patients
(72.7%) had hydatidiform mole, four (18.2%) had
choriocarcinoma, and two (9.1%) had invasive mole.
Recorded clinical characteristics included age, parity,
initial hCG at the time of hospitalization, treatment
methods, pathologic findings, and pregnancy outcome,
which was followed for 1 year or more after completion
of treatment. High-risk, middle-risk, and low-risk GTD
categories were assessed using the FIGO 2000 scoring
system for GTD [3].
Therapeutic methods in this study were suction
evacuation, hysterectomy, single-agent chemotherapy
with methotrexate (1 mg/kg intramuscularly, IM, on
days 1, 3, 5 and 7, and with folinic acid 0.1 mg/kg IM
on days 2, 4, 6 and 8, every 14 days as a cycle) or
combination chemotherapy with EMA-CO (Day 1:
etoposide 100 mg/m2 intravenously, IV, over 30 minutes,
methotrexate 100 mg/m2 IV bolus and 200 mg/m2 IV
as continuous 12-hour infusion, and actinomycin D
0.5 mg/m2 IV bolus; Day 2: etoposide 100 mg/m2 IV
over 30 minutes, folinic acid 15 mg IM every 6 hours
for four doses beginning 24 hours after the start of
methotrexate, actinomycin D 0.5 mg/m2 IV bolus; Day
8: cyclophosphamide 600 mg/m2 IV over 30 minutes,
vincristine 1 mg/m2 IV bolus; every 14 days as a cycle)
[4]. Persistent GTD was evaluated using one of the
following criteria: serum hCG of more than 20,000
mIU/mL at more than 4 weeks after evacuation; rising
hCG in consecutive serum samples; hCG in three
consecutive serum samples not rising or falling
significantly; and hCG in excess of the normal range at
6 months after evacuation. Patients with persistent
GTD required and received one or more additional
courses of single-agent chemotherapy or crossed over
to combination chemotherapy.
Serum hCG was measured every 2 weeks, and once
the level had reached the lower limit of measurement
(< 10 mIU/mL), it was measured monthly for 6 months.
Patients were then followed-up every 2 months for a
total of 1 year. Patients were strongly advised not to
conceive for at least 1 year after completion of
chemotherapy and/or hCG follow-up.
All patients were regularly followed-up in the
gynecologic clinic at Chung Shan Medical University
Hospital and questioned concerning the desire for fur-
ther pregnancy following remission of disease.
Results
The clinical characteristics of the patients are shown in
Table 1. The mean age was 32.5 years. Nulliparous wom-
en were the majority of the population in this study
at 45.5%. The median initial hCG at admission was
94,798.1 mIU/mL. Of the 22 patients, 16 had hydatidi-
form mole, three had choriocarcinoma, one had meta-
static choriocarcinoma, and two had invasive mole.
Persistent GTD was diagnosed in 15 patients who dem-
onstrated an abnormal hCG titer at follow-up. These
patients received more than one cycle of sequential
chemotherapy until the hCG level declined to the normal
range. Radiography showed that all patients were free
of metastasis in the lungs and brain. The patient with
metastatic choriocarcinoma was identified by patho-
logic findings which indicated metastasis into the
right adnexa and to the colon serosa after debulking
surgery. No metastasis was found on chest X-ray or
brain computed tomography in this patient. Based on
the FIGO 2000 scoring system for GTD [3], two patients
were high risk, 14 were middle risk, and six were low
risk (Table 1).
Table 2 shows the therapeutic methods used. Two
patients with invasive moles underwent hysterectomy
and then received chemotherapy. Seven patients
(31.8%) were treated using only suction evacuation and
were in complete remission during follow-up. Patients
Table 1. Clinical characteristics of 22 patients
Mean age, yr (range) 32.5 (21–50)
Parity, n (%)
   0 10 (45.5)
   1 09 (40.9)
   2 02 (9.1)
   3 01 (4.5)
Median of hCG, mIU/mL 94,798.1
  (range)   (484.7–1,337,572.0)
Hydatidiform mole, n (%)
   Partial 05 (22.7)
   Complete 11 (50.0)
Invasive mole, n (%) 02 (9.1)
Choriocarcinoma, n (%) 03 (13.6)
Metastatic choriocarcinoma, n (%) 01 (4.5)
Persistent GTD, n (%) 15 (68.2)
Scoring system, n (%)
   High risk 02 (9.1)
   Middle risk 14 (63.6)
   Low risk 06 (27.3)
hCG = human chorionic gonadotropin; GTD = gestational trophoblastic
disease.
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with persistent GTD underwent suction evacuation or
surgery and then received chemotherapy with
methotrexate or EMA-CO. They all had an excellent
response at follow-up.
After at least 1 year of follow-up, eight patients
(36.4%) conceived. Six (27.3%) delivered a healthy
term baby and two (9.1%) had a blighted ovum so
underwent therapeutic abortion. The mean age of
patients who conceived was 29.3 years. Patients who
did not conceive had completed their family and their
mean age was 34.4 years.
Patients with GTD had an excellent response to
treatment and no mortality was observed in this study.
Discussion
Follow-up with serial hCG measurement is a good
method to determine disease status in patients with
GTD and identifies patients with progression to per-
sistent GTD who required subsequent chemotherapy
[5]. Patients with persistent GTD were treated with
indicated chemotherapy until the hCG level reached the
normal range. Laboratory assessment of hCG in patients
with GTD will usually give a very high value, but it can
reveal a normal level compatible with a normal preg-
nancy. After molar evacuation, once a patient reaches
an undetectable hCG level, the risk of developing per-
sistent GTD is less than 1% [6]. Lurain et al reported
that approximately 20% of women will undergo further
treatment for suspected persistent GTD following
evacuation of a hydatidiform mole [7]. Therefore, follow-
up hCG after treatment of GTD is an important tool, no
matter what the initial value.
Pregnancy is not advised until completion of 1 year
or more of follow-up after disease remission, and all
patients in this study followed these recommendations.
Matsui et al reported 102 (79.1%) term live births, one
(0.8%) stillbirth, one (0.8%) premature delivery, 12
(9.3%) spontaneous abortions, nine (7.0%) therapeutic
abortions, and four (3.1%) repeated moles among 129
patients with GTT who subsequently conceived following
treatment and primary remission [8]. In this study, the
eight patients who conceived were less than 30 years old
and unmarried. Patients older than 30 had completed
their family and did not desire additional pregnancy.
Despite strong discouragement and explanation,
some patients become pregnant before the completion
of hCG follow-up. Tuncer et al [9] and Lan et al [10]
reported pregnancy outcomes in patients who conceived
within 1 year after chemotherapy for GTD. They found
that it was not necessary to terminate pregnancy but
that the pregnancy had to be kept under careful
surveillance. In contrast, Matsui et al found that the
frequency of spontaneous abortion in patients who
conceived within 6 months was significantly higher than
that in patients who conceived after more than 6 months
[8]. They suggested that it would be better to avoid
pregnancy for at least 6 months after completion of
chemotherapy. Gougeon reported that the full span of
growth from the primordial to Graafian follicle is in the
order of 6–12 months [2]. Anti-cancer drugs affect
developing follicles and oocytes for a short interval after
chemotherapy, and genetic damage or teratogenic ef-
fects can be induced. The patients in this study were
strongly advised to avoid pregnancy and use reliable
contraception for 12 months following completion of
chemotherapy. This was to ease the anxiety and fear of
fetal anomalies resulting from anti-cancer drugs.
GTD had an excellent response to, and prognosis
after, chemotherapy. Patients may anticipate a normal
future reproductive outcome. In this study, patients
with GTT who had completed childbirth and had no
desire for further pregnancy received aggressive sur-
gery such as hysterectomy. In patients with a new preg-
nancy, an ultrasound examination can confirm normal
gestational development during the first trimester.
Tuncer et al suggested that at the completion of any new
pregnancy, the placenta or products of conception
should undergo pathologic examination and hCG should
be measured 6 weeks later to exclude occult persis-
tent trophoblastic disease [9]. In conclusion, although
pregnancy after successful treatment for GTD has been
reported in many studies, careful follow-up should be
ensured after treatment and in antepartum and
postpartum care.
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